Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
- Seeking Series B investment for next phase of clinical trials
Call:
+44 (0) 1865 784074
Oxford Vacmedix UK Limited:
Oxford, UK, OX4 4GA
Email:
enquiries@oxfordvacmedix.com
Company News
The OVM-200 Phase 1 trial has met both primary and secondary endpoints and additionally early observations of clinical efficacy have been seen. Oxford, UK – 21st
The initial part of the Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer immunotherapy has been published in eClinical Medicine, a journal of the Lancet gro
All patients have completed treatment in the Phase 1 trial of Oxford Vacmedix’s lead cancer vaccine OVM-200 Oxford, UK – 17 November 2025 Press Release - Las
The Phase 1 trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been fully recruited in only three months since the new extended dosing protocol was imple
Extended dosing of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been approved by the MHRA for use in the ongoing Phase 1 clinical trial Oxford, UK - 20th F
OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable and sterile four years post manufacture – a major milestone for O
Contact Us
If you have any questions or want to get in touch, please contact our team.
(c) 2025 Oxford Vacmedix UK Limited | Company Registration: 07994205
English